Treatments for relapsed or refractory rhabdomyosarcoma in children and young people

Posted on 14 January 2021

CRD Clinical Academic Dr Bob Phillips is leading a new study to understand treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma. The study is funded by the Children’s Cancer and Leukaemia Group (CCLG) Special Named Funds.

The study includes a systematic review of all previous early phase studies in relapsed or refractory rhabdomyosarcoma to see how effective the different treatments are, and an interview study with patients and families to help understand the decision-making process about treatments, and how to best support families faced with these choices. The research will result in a ‘best practice statement’ which will provide advice and support to clinicians and families about important things to consider when discussing treatment options.

The study will commence in the Spring of 2021 and be completed by Autumn 2022. Further details can be found here.